Pro-Dex, Inc.

NASDAQ:PDEX

Medical - Instruments & Supplies

Healthcare
$63.94 +5.86%

+$3.54 today

Market cap
$204.61M
Beta
-0.00
P/E (TTM)
17.1
EPS (TTM)
$3.75
52W Low $23.47High $68.99

Volume 0.04M

Average 0.04M

PDEX Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Pro-Dex, Inc.NASDAQ: PDEX

Net Income · Q3 FY2026 · quarter ended Mar 2026

Net income grows, but more slowly than its trailing trend

Q3 FY2026 net income of $3.94M rose 20.2% year over year, behind the +28.1% change in trailing-twelve-month net income. Sequentially, it rose 80.1% from the prior quarter. Over 3 fiscal years it compounded at +25.2% a year.

Context

  • Net income amounted to 13.5% of revenue in FY2025, up 9.5 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 1 analysts of $13.07M (+45.6%) for the fiscal year ending Jun 2026, a slowdown from the +322.1% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.94M+80.1% QoQ
Last fiscal yearJun 2025
$8.98M+322.1% YoY
LTMMar 2026
$12M+28.1% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+20.2%+85.6%+65.3 pp
1 year+322.1%+45.6%-276.5 pp
3-year CAGR+25.2%+8.6%-16.6 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
8.98M USD
Year-over-year change
+322.1%
4-year CAGR
+18.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How PDEX compares with its peers on the latest reported figures

  • PDEX's LTM Mar 2026 net income of $12M is the 8th largest of the 9 companies compared; the peer median is $26.95M.
  • Its year-over-year change of +28.1% is the 4th highest of 9, against a peer median of +16.8%.
  • Net income amounts to 16.1% of revenue for PDEX, versus a peer median of 34960.6%.
PDEX Competitors Peer median
Net Income for PDEX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LUCDLucid Diagnostics Inc.LTM Mar 2026$26.68B +43056.2%+1.1%519699.0%
STSSSkyAI, Inc.LTM Mar 2026$358.5M +5514.8%+287.7%90325.9%
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$50.14M +11.8%-8.1%145.8%
SERASera Prognostics, Inc.LTM Mar 2026$32.14M -2.6%-10.3%56386.0%
GLSIGreenwich LifeSciences, Inc.LTM Mar 2026$21.76M +31.3%+35.2%—
CGTXCognition Therapeutics, Inc.LTM Mar 2026$19.58M -41.2%+3.2%—
MBOTMicrobot Medical Inc.LTM Mar 2026$14.21M +21.8%-0.1%13535.2%
PDEXPro-Dex, Inc.LTM Mar 2026$12M +28.1%+25.2%16.1%
APYXApyx Medical CorporationLTM Mar 2026$9.05M -55.1%-21.9%16.2%
Peer median (excluding PDEX) $26.95M+16.8%+0.5%34960.6%

Competitors are the stored peer set for PDEX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Net Income4.57M4.57M7.07M2.13M8.98M
Depreciation & Amortization726K726K857K1.16M1.24M
Deferred Income Tax(63K)(63K)264K(1.56M)140K
Stock-Based Compensation1.28M1.28M766K605K555K
Change in Working Capital(6.54M)(6.54M)396K(225K)(10.45M)
Accounts Receivables(4.45M)(4.45M)5.43M(3.94M)(2.55M)
Inventory(4.24M)(4.24M)(3.49M)898K(6.94M)
Accounts Payables1.99M1.99M(1.15M)2.44M179K
Other Working Capital162K162K(394K)376K(1.14M)
Other Non-Cash Items(820K)(820K)(3.9M)4.1M(2.14M)
Operating Cash Flow(847K)(847K)5.46M6.2M(1.68M)
Capital Expenditures(1.67M)(1.67M)(974K)(983K)(1.25M)
Acquisitions (Net)00000
Purchases of Investments(334K)(334K)0(1.25M)0
Sales of Investments770K770K89K01.31M
Other Investing Activities(33K)(33K)00(304K)
Investing Cash Flow(1.24M)(1.24M)(885K)(2.23M)(238K)
Debt Repayment8.79M756K(809K)(816K)3.48M
Common Stock Issued96K00042K
Common Stock Repurchased(5.54M)(1.61M)(1.55M)(3.51M)(3.5M)
Dividends Paid00000
Other Financing Activities(4.14M)60K(134K)50K(305K)
Financing Cash Flow(790K)(790K)(2.49M)(4.27M)(292K)
Effect of Forex Changes00000
Net Change in Cash(2.87M)(2.87M)2.09M(305K)(2.21M)
Free Cash Flow(2.52M)(2.52M)4.49M5.22M(2.93M)

Pro-Dex, Inc.

NASDAQ:PDEX

Intrinsic Alpha fair value

Locked

Current Price

$63.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.